Alkermes plc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-6.7%projected annual EPS growth
Analyst Coverage
17analysts covering
FY Revenue (est.)
$1.8Bnext fiscal year
Monitoring Framework
Key Performance Indicators
Proprietary Product Net Sales Quarterly338.1MTarget: Greater than $1.7 billion for FY 2026
LUMRYZ Net Sales Quarterly39.5MTarget: $315 million to $335 million for FY 2026
LYBALVI Net Sales Quarterly92.4MTarget: $380 million to $400 million for FY 2026
Watch Items
- Alixorexton (ALKS 2680) Phase 3 Brilliance Studies Enrollment and ProgressTrigger: Initiation of Phase 3 trials in NT1 and NT2Action: Monitor clinical trial updates, patient enrollment rates, and safety/efficacy readouts to validate the long-term sleep medicine growth thesis.
- Vibrance-3 Phase 2 Study of Alixorexton in Idiopathic HypersomniaTrigger: Completion of Phase 2 trial expected in Q4 2026Action: Evaluate topline data for idiopathic hypersomnia to assess pipeline expansion potential beyond narcolepsy.
- Integration of Avadel Pharmaceuticals and LUMRYZ Commercial ScalingTrigger: LUMRYZ quarterly sales run-rateAction: Track market share gains of LUMRYZ against established once-nightly and twice-nightly oxybate formulations.
Research as of 2 Sep 2026